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The c-Jun NH2-terminal kinase (JNK)-interacting protein (JIP) group of scaffold proteins (JIP1, JIP2, and
JIP3) can interact with components of the JNK signaling pathway and potently activate JNK. Here we describe
the identification of a fourth member of the JIP family. The primary sequence of JIP4 is most closely related
to that of JIP3. Like other members of the JIP family of scaffold proteins, JIP4 binds JNK and also the light
chain of the microtubule motor protein kinesin-1. However, the function of JIP4 appears to be markedly
different from other JIP proteins. Specifically, JIP4 does not activate JNK signaling. In contrast, JIP4 serves
as an activator of the p38 mitogen-activated protein (MAP) kinase pathway by a mechanism that requires the
MAP kinase kinases MKK3 and MKK6. The JIP4 scaffold protein therefore appears to be a new component
of the p38 MAP kinase signaling pathway.
Seminal studies of the yeast Saccharomyces cerevisiae have
established the concept that mitogen-activated protein (MAP)
kinase (MAPK) signaling pathways can be assembled into
functional signaling modules by protein-protein interactions
(5). Examples include studies on the role of the Ste5p scaffold
protein in the mating MAP kinase signaling pathway (5) and
the role of Pbs2p in the osmosensing MAP kinase signaling
pathway (22). Furthermore, it has been demonstrated that an
artificial scaffold in yeast can direct both activation and signal-
ing specificity within a MAP kinase signaling module (8, 21).
Recent studies of mammalian cells have demonstrated that
scaffolding interactions can participate in the regulation of
MAP kinase signaling modules (19). Thus, the KSR scaffold
protein (20) and the MP1 scaffold protein, together with the
accessory proteins Morg1 and p14 (14, 23, 28, 32, 35), can
organize signaling by the ERK group of MAP kinases. Simi-
larly, the OSM scaffold protein can coordinate signaling by the
p38 MAP kinase signaling pathway (30). Furthermore, a num-
ber of potential scaffold proteins have been implicated in the
regulation of JNK signaling modules (19), including members
of the JIP protein family (37).
JIP1 is the founding member of the c-Jun NH2-terminal
kinase (JNK)-interacting protein (JIP) group of scaffold pro-
teins and is structurally related to JIP2 (4, 33, 37). Gene dis-
ruption studies with mice (9, 29, 34) have demonstrated that
JIP1 contributes to JNK activation in neurons following expo-
sure to an anoxic insult (9, 34) and is also required in adipose
tissue for JNK activation in models of type II diabetes (11).
Together, these data provide strong genetic evidence that the
JIP proteins can function to regulate JNK signaling. However,
and very importantly, these data also establish that JIP pro-
teins are required for the ability of selective stimuli to activate
JNK and are not core components of the JNK signaling path-
way that are essential for multiple stimuli to activate JNK (19).
More recently, a new member of the JIP protein kinase
group, JIP3, was identified (10, 13). JIP3 is structurally distinct
from JIP1 and JIP2, but it shares many of the biochemical
properties of JIP1 and JIP2. Thus, all three JIP proteins bind
JNK, the MAP kinase kinase (MAP2K) MKK7, and members
of the mixed-lineage protein kinase group of MAP kinase
kinase kinases (MAP3Ks), and all three JIP proteins can
strongly activate JNK signaling (10, 13). In addition, all three
JIP proteins interact with the tetratricopeptide repeat (TPR)
domain of the light chain of the microtubule motor protein
kinesin-1 and can be transported as cargo molecules along
microtubule networks within cells (1, 31, 34). Targeted disrup-
tion of the Jip3 gene in mice causes major defects in the
development of the brain, including defects in the telence-
phalic commissure, and death immediately following birth be-
cause of a failure to breathe (12).
Sequences of cDNA related to JIP3, including JIP3, JIP3,
Syd-1, SPAG9, and JLP (1, 13, 15, 26), have been identified by
searching libraries and databases. Here we describe a new
JIP3-related protein (JIP4) that shares many of the properties
of JIP3, such as its ability to bind to JNK and kinesin light
chain. However, the function of JIP4 appears to differ from
those of the other members of the JIP protein family because
it does not activate JNK. In contrast, we found that JIP4 can
activate p38 MAP kinase.
MATERIALS AND METHODS
Molecular cloning of JIP4. The JIP4 cDNA was isolated from a mouse testis
ZAPII library (Stratagene) by plaque hybridization using a 32P-labeled JIP3
cDNA probe. The largest clone obtained (3,711 bp) included the complete open
reading frame of JIP4 (1,142 amino acids) with in-frame termination codons in
the 5 and 3 noncoding regions. Sequence analysis was performed using an
Applied Biosystems machine.
Plasmids. The expression vectors for MAPK, MAP2K, MAP3K, JIP1, JIP2,
JIP3, and KLC were described previously (13, 34). Expression vectors for JIP4
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were constructed by subcloning PCR fragments in the plasmids pCDNA3 (In-
vitrogen Inc.) and pGEX-5X1 (Amersham Pharmacia Biotech Inc.).
Antibodies. The antibodies to the Flag epitope tag (M2; Sigma Chemical Co.),
the hemagglutinin (HA) epitope tag (12CA5; Roche), the T7 epitope tag (No-
vagen Inc.), the V5 epitope tag (Invitrogen Inc.), glutathione S-transferase (GST;
Pharmacia-LKB Biotech Inc.), -tubulin (Sigma Chemical Co.), and protein
disulfide isomerase (Stressgen) were purchased from indicated suppliers. Anti-
bodies to Grasp 65, STT3, and KLC were provided by C. Suetterlin, R. Gilmore,
and L. S. Goldstein, respectively. Antibodies to p38 MAP kinase (Pharmingen),
JNK1 (Santa Cruz), and ERK2 (Santa Cruz) were used for immune complex
kinase assays. Antibodies to MKK3 (Santa Cruz) and MKK6 (Cell Signaling)
were used for immunoblot analysis.
Cell culture. Murine embryo fibroblasts (MEF) were prepared from wild-type,
Mkk3/ (16, 36), Mkk6/ (27), and Mkk3/ Mkk6/ (2) embryos. These
MEF and COS7 cells (obtained from the American Type Culture Collection)
were grown in Dulbecco’s modified Eagle’s medium (DMEM) supplemented
with 10% fetal bovine serum in an incubator with humidified air (5% CO2) at
37°C. Transfection with plasmid expression vectors was performed using the
Lipofectamine reagent (Invitrogen). PC12 cells (obtained from the American
Type Culture Collection) were cultured at 37°C on collagen-coated plastic dishes
in DMEM supplemented with 0.5 mM glutamine, 10% horse serum, and 5%
fetal bovine serum (Invitrogen) in a humidified incubator (10% CO2). The cells
were differentiated by incubation in DMEM supplemented with 1% horse serum,
0.5 mM glutamine, and 50 ng of nerve growth factor per ml.
Biochemical assays. Cultured cells were extracted in Triton lysis buffer (20
mM Tris-Cl [pH 7.4], 137 mM sodium chloride, 2 mM EDTA, 25 mM -glyc-
erophosphate, 2 mM sodium pyrophosphate, 1 mM sodium orthovanadate, 1
mM phenylmethylsulfonyl fluoride, 10 g of leupeptin/ml, 5 g of aprotinin/ml,
10% glycerol, 1% Triton X-100). Proteins were immunoprecipitated by incuba-
tion with antibodies immobilized on protein G-Sepharose beads (Amersham
Pharmacia Biotech Inc.) for 3 h at 4°C. Immunoblot analysis was carried out by
enhanced chemical luminescence detection (Kirkegaard & Perry Inc.). GST
fusion proteins were purified by incubation with glutathione-agarose beads (Am-
ersham Pharmacia Biotech Inc.). Methods for binding assays using in vitro-
translated proteins and immune complex kinase assays were described earlier
(13, 33, 37). The effect of scaffold proteins on JNK activity was examined in
COS7 cell transfection assays using the in-gel method with 250 g of GST–c-Jun
per ml polymerized in the gel (13).
Subcellular fractionation. Cultured cells were fractionated into membrane
and soluble fractions by suspension in hypotonic lysis buffer (5 mM Tris-Cl [pH
7.5], 1 mM MgCl2, 0.1 mM EDTA, 1 mM EGTA, 5 g of aprotinin/ml, 10 g of
leupeptin/ml) by incubation on ice and passage through a 21-gauge needle. The
extracts were clarified by centrifugation at a low speed (1,000 	 g) and loaded
onto a 20% (wt/vol) sucrose cushion (in lysis buffer) and centrifuged at a relative
centrifugal force of 350,000 in an airfuge (Beckman Instruments). The mem-
brane fraction was dissolved in 1% sodium dodecyl sulfate (SDS). The proteins
(75 g) were examined by immunoblot analysis.
Immunofluorescence studies. Cells were grown on glass coverslips, fixed by
incubation at 20°C in cold methanol (10 min), and permeabilized with 0.2%
Triton X-100 in phosphate-buffered saline (PBS). After blocking by incubation in
3% (wt/vol) bovine serum albumin (BSA) in PBS (1 h), the coverslips were
incubated at 4°C (16 h) in primary antibodies diluted in 3% BSA plus 2 U of
RNase One (Promega) per ml. The coverslips were washed in 0.5% Tween 20 in
PBS and incubated in tetramethyl rhodamine isocyanate-conjugated anti-rabbit
immunoglobulin and fluorescein-conjugated anti-mouse immunoglobulin sec-
ondary antibodies (Jackson ImmunoResearch Inc.) and nucleic acid marker
TOTO3 (Molecular Probes) in 3% BSA-PBS (1 h). The coverslips were mounted
in Vectashield (Vector Laboratories Inc.). Fluorescence microscopy was per-
formed with a Leica confocal microscope.
Nucleotide sequence accession number. The sequence of the full-length cDNA
encoding JIP4 was deposited in GenBank with accession number AY823270.
RESULTS
Molecular cloning of JIP4. We have previously reported the
molecular cloning of the scaffold protein JIP3 (13). Database
analysis indicated the presence of partial cDNA fragments
corresponding to a JIP3-related gene (13). We therefore screened
a cDNA library to obtain a full-length clone. The largest clone
obtained (3,711 bp) included the complete open reading frame
for a large protein (1,142 amino acids) that is related to JIP3,
with in-frame termination codons in the 5 and 3 untranslated
regions. We have named this protein JIP4. The sequence align-
ment of JIP3 and JIP4 indicated similarities that extended
from the NH2 terminus to the COOH terminus (Fig. 1A; see
Fig. S1 in the supplemental material). The major difference
between JIP3 and JIP4 was that JIP3 contained an NH2-ter-
minal extension (170 amino acids) that was not present in JIP4.
A computer-assisted sequence analysis of JIP3 and JIP4 re-
vealed the presence of an extended coiled-coil domain and a
leucine zipper in the NH2-terminal region together with a JNK
binding domain, a JNK phosphorylation domain, and a puta-
tive transmembrane domain that are conserved in JIP3 and
JIP4 (Fig. 1A; see Fig. S1 in the supplemental material).
A comparison of the deduced sequence of the JIP4 mRNA
and the mouse genomic sequence (GenBank) revealed that Jip4
is a large gene which is located on chromosome 11 and that this
gene consists of 31 exons (Fig. 2). The Jip4 gene encodes at
least three proteins (JIP4, JLP, and SPAG9) that differ in uti-
lization of 5 exons but share common 3 exons. The 5 untrans-
lated region of the JIP4 mRNA includes sequences derived
from exons 2 through 5 (with an in-frame termination codon in
exon 3 and an initiation codon in exon 5) that are fused to
sequences derived from exons 7 through 31. In contrast, the 5
region of the JLP mRNA (15) is encoded by exon 1 (with no
in-frame termination codon but with an initiation codon in
exon 1) that is fused to sequences derived from exons 2, 4, 5,
and 7 through 31. Finally, the sperm-associated antigen 9 pro-
tein (SPAG9) mRNA (26) is encoded by exon 6 (with no in-
frame termination codon but with an initiation codon in exon
6) that is fused to sequences derived from exons 7 to 31. These
data indicate that the JIP4 protein is a novel product of the Jip4
gene and shares some similarities with both JLP and SPAG9.
Expression of JIP4 in murine tissues. The expression of
JIP4 mRNA in different murine tissues was examined by North-
ern blot analysis (Fig. 1B). Two major transcripts, of 4.8 and
8.9 kb, were detected. The 4.8-kb RNA is most abundant in the
testis, while the larger transcript of 8.9 kb is more abundant in
the brain, kidney, liver, heart, and other tissues. This broad
tissue distribution of JIP4 differs from the selective expression
of JIP3 in the brain and at low levels in the heart and testis.
JIP3 and JIP4 are soluble cytoplasmic proteins. We have
previously identified JIP3 as a soluble cytoplasmic protein (13).
However, this conclusion has been questioned in a recent study
that reported the identification of JIP3 as a transmembrane
protein (1). Furthermore, the JIP4-related protein SPAG9 has
been reported to be a cell surface membrane protein (26).
Indeed, hydropathy plots indicate that JIP4 contains a putative
transmembrane domain (residues 820 through 836) (Fig. 1A;
see Fig. S1 in the supplemental material). The sequence of the
corresponding region of JIP3 (residues 985 through 1001) is
similar but is significantly less hydrophobic because one of the
residues in this region of JIP4 (Ile) is replaced with a charged
residue in JIP3 (Arg) (Fig. 1A; see Fig. S1 in the supplemental
material). The primary sequence of JIP4 and possibly that of
JIP3 therefore suggest that these proteins could span a mem-
brane.
We examined whether JIP3 and JIP4 are integral membrane
proteins and whether these proteins are soluble in the cyto-
plasm. Membrane and soluble fractions of cultured cells were
prepared. Immunoblot analysis indicated that JIP3 and JIP4
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were present in the soluble fractions (Fig. 3A and B). Similar
results were obtained when the endogenous JIP3 and JIP4
proteins were examined (Fig. 3B) and when ectopically ex-
pressed JIP3 and JIP4 were examined (Fig. 3A). Control stud-
ies confirmed that the microsomal membrane protein STT3
was detected in the membrane fraction (Fig. 3B). This analysis
indicated that while JIP4 has the potential to be a membrane
protein, both JIP3 and JIP4 were detected in cultured cells as
soluble proteins.
To confirm that JIP3 and JIP4 are soluble cytoplasmic pro-
teins, we examined the subcellular distributions of JIP3 and
JIP4 by immunofluorescence analysis. The JIP4 antibody we
prepared was useful for an immunoblot analysis of the endog-
enous expression of JIP4 (Fig. 3B), but it was not useful for an
immunocytochemical analysis because of nonspecific back-
ground staining (data not shown). We therefore performed an
immunofluorescence analysis using transfected cultured cells
that express recombinant JIP3 and JIP4. Immunofluorescence
microscopy demonstrated that JIP3 and JIP4 were distributed
throughout the cytoplasm (Fig. 4). Disruption of microtubules
with nocodazole caused a more punctate staining pattern for
both JIP3 and JIP4, but the staining remained restricted to the
cytoplasm (Fig. 4A). To test whether JIP3 or JIP4 might co-
localize with an organelle, we compared the distributions of
JIP3 and JIP4 with markers for mitochondria (mitotracker
dye), Golgi (Grasp 65), and the endoplasmic reticulum (pro-
tein disulfide isomerase). This analysis did not demonstrate an
association of JIP3 and JIP4 with these organelles (Fig. 4B).
Together, these data indicate that JIP3 and JIP4 are broadly
distributed cytoplasmic proteins.
FIG. 1. Primary structures and expression levels of JIP3 and JIP4. (A) Schematic representation of the domain structures of JIP3 and JIP4. We
have previously reported the primary sequence of JIP3 (GenBank accession numbers AF178636 and AF178637) (13). We now report the primary
sequence of JIP4 (GenBank accession number AY823270). TM, transmembrane. (B) Northern blot analysis of 2 g of poly(A) RNA isolated
from several murine tissues. The blot was probed with double-stranded probes derived from JIP3, JIP4, and -actin. The migration of RNA
standards is indicated on the left.
VOL. 25, 2005 MOLECULAR CLONING OF JIP4 2735
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JIP4 interacts with kinesin light chain. JIP3 is known to
interact with kinesin light chain (KLC1), a component of the
microtubule motor protein kinesin-1 (1). To test whether JIP4
also interacts with kinesin-1, we performed a coimmunopre-
cipitation analysis. These assays demonstrated that KLC1 co-
immunoprecipitated with both JIP3 and JIP4 (Fig. 3C). Inter-
estingly, the interaction of KLC1 with JIP4 was greater than
that that detected for KLC1 with JIP3.
The TPR domain of KLC1 has been suggested to be respon-
sible for cargo binding, and this domain of KLC1 does interact
with JIP1, JIP2, and JIP3 (1, 31, 34). To test whether JIP4 also
binds to the TPR domain of KLC1, we examined the interac-
tions of JIP3 and JIP4 with KLC1 in vitro. These data dem-
onstrated that the TPR domain of KLC1 binds to both JIP3
and JIP4 (Fig. 3E). Binding of JIP3 and JIP4 to other domains
of KLC1 was not observed (data not shown). To identify the
region of JIP3 and JIP4 that interacts with the TPR domain of
KLC1, we examined the effect of deletion mutations in JIP3
and JIP4 on their binding to KLC1 (Fig. 3F and data not
shown). This analysis demonstrated that the leucine zipper
domain of JIP3 and JIP4 was required for their binding to
KLC1 (Fig. 3F). Together, these data demonstrate that binding
to the TPR domain of KLC1 is mediated by the leucine zipper
domain of JIP3 and JIP4. This interaction contrasts with those
of JIP1 and JIP2, which bind to the TPR domain of KLC1 by
an interaction that is mediated by the COOH terminus of JIP1
and the COOH terminus of JIP2 (31, 34). Thus, although the
TPR domain of KLC1 binds to all four JIP proteins, the modes
of binding by the TPR domain to JIP1 and JIP2 and to JIP3
and JIP4 are distinct.
To examine whether the interaction of KLC1 with JIP pro-
teins might be regulated by extracellular stimuli, we examined
the effect of serum starvation on the coimmunoprecipitation of
JIP proteins with KLC1 (Fig. 3D). Serum starvation (24 h) was
found to cause decreased interactions of JIP3 and JIP4 with
KLC1. Similarly, a small decrease in KLC1 binding to JIP1 was
detected, but no change in the interaction of JIP2 with KLC1
was observed. These observations confirm that the regulation
of the interaction of JIP4 and KLC1 is similar to the regulation
of the interaction of KLC1 and other JIP proteins, particularly
JIP3.
JIP4 binds JNK but does not interact with MKK7 or MLK3.
The sequence similarity between JIP3 and JIP4 indicates that
these proteins may have similar functions. It is established that
the JNK binding domain of JIP3 interacts with JNK (13). The
JNK binding domain of JIP3 is conserved in JIP4 (Fig. 1A)
and, as expected, similar amounts of JNK were found to co-
immunoprecipitate with JIP3 and JIP4 (Fig. 5A). Like JIP3
(13), JIP4 was not found to coimmunoprecipitate with other
members of the MAP kinase family, including ERK2 and p38
MAP kinase (Fig. 5A). These observations confirm that JIP3
and JIP4 may have similar functions.
JIP3 also interacts with the MAP2K isoform MKK7 and the
MAP3K isoform MLK3 (13). Comparative studies confirmed
the interaction of JIP3 with MKK7 and MLK3, but no inter-
action of JIP4 with these MAP2K and MAP3K isoforms was
detected (Fig. 5B and C).
Coimmunoprecipitation assays demonstrated that JIP4 did
interact with the MAP3K ASK1 (Fig. 5D). We have previously
reported that JIP3 does not bind ASK1 in a GST pull-down
assay (13). To confirm this conclusion, we compared the inter-
action of ASK1 with JIP3 to the interaction of ASK1 with JIP4
FIG. 2. Several proteins are encoded by different transcripts derived from the Jip4 gene by alternative splicing. The gene that encodes JIP4 is
located on mouse chromosome 11 and consists of a total of 31 exons. The structure of the gene is illustrated schematically. The gene encodes three
proteins (JIP4, JLP, and SPAG9) that are encoded by the selective inclusion of different 5 exons of the Jip4 gene. The JIP4 mRNA is encoded
by exons 2, 3, 4, 5, and 7 through 31 and includes an in-frame termination codon in the 5 untranslated region. The JLP mRNA is encoded by exons
1, 2, 4, 5, and 7 through 31. The SPAG9 mRNA is encoded by exons 6 and 7 through 31. In-frame termination codons in the 5 untranslated region
of JLP and SPAG9 are not present. The GenBank entries for the genes that encode JIP1, JIP2, and JIP3 are designated Mapk8ip1, Mapk8ip2, and
Mapk8ip3. This nomenclature suggests that the GenBank entry for the gene that encodes JIP4 should be designated Mapk8ip4.
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by coimmunoprecipitation analysis (Fig. 5D). These assays
demonstrated that ASK1 binds JIP3 more strongly than JIP4.
It is most likely that our previous failure to detect an inter-
action between ASK1 and JIP3 was caused by the use of a
GST-fusion protein strategy in our earlier experiments. Our
coimmunoprecipitation analysis demonstrates that ASK1 can
bind both JIP3 and JIP4 (Fig. 5D).
JIP4 is not a scaffold for the JNK-MKK7-MLK3 signaling
module. The absence of binding of JIP4 to MKK7 and MLK3
suggested that JIP4 may not function to assemble a functional
JNK signaling module. To test this hypothesis, we compared
the abilities of JIP3 and JIP4 to potentiate the activation of
JNK by MLK3. This analysis demonstrated that, as expected,
JIP3 strongly increased MLK3-stimulated JNK activation (Fig.
6). However, JIP4 was ineffective as an activator of JNK in this
assay (Fig. 6).
We have previously reported that JIP proteins function as
oligomers (most likely dimers) (13, 37). If JIP4 is a nonfunc-
tional JNK scaffold protein, it is possible that JIP4 might act as
a natural antagonist of the JNK scaffold activity of other JIP
proteins. JIP1 and JIP2 form homo- and hetero-oligomers
(37). JIP3 can form homo-oligomers and can also interact with
JIP2 (13). Coimmunoprecipitation assays demonstrated that
JIP4 can also form homo-oligomers, but no interaction of JIP4
with JIP1, JIP2, or JIP3 was detected (Fig. 7). The lack of an
interaction between JIP4 and other JIP proteins suggests that
JIP4 most likely does not act as an antagonist but is probably
inactive as a JNK scaffold. Indeed, direct measurements of
JIP-mediated potentiation of MLK3-stimulated JNK signaling
demonstrated that the coexpression with JIP4 did not alter
JNK activation (Fig. 6).
JIP4 is phosphorylated by JNK and p38 MAP kinase. It is
established that JNK phosphorylates JIP3 on three sites and
that JIP3 is not a substrate for ERK2 or p38 MAP kinase
(13). Two of these three phosphorylation sites on JIP3 (Thr-
267 and Thr-288) are conserved in JIP4 (Thr-97 and Thr-113),
FIG. 3. The cytoplasmic proteins JIP3 and JIP4 interact with kinesin light chain. (A) JIP3 and JIP4 are cytoplasmic proteins. Flag-tagged JIP
proteins were expressed in COS cells. Cytosolic (C) and membrane (M) fractions of the cells were prepared and examined by an immunoblot
analysis using antibodies to the Flag-tagged JIP3 and JIP4. (B) Nerve growth factor-differentiated PC12 cells were separated into cytosolic (C) and
membrane (M) fractions. Endogenously expressed JIP3 and JIP4 were examined by immunoblot analysis using antibodies to JIP3 and JIP4. An
immunoblot analysis using an antibody to the microsomal membrane protein STT3 was used as a control for cell fractionation. (C) Flag-tagged
JIP3 and JIP4, together with V5 epitope-tagged kinesin light chain 1 (KLC), were expressed in COS cells. The cell lysates were examined by
immunoprecipitation (IP) and immunoblot (IB) analyses using the indicated epitope tag antibodies. (D) COS cells expressing epitope-tagged JIP1,
JIP2, JIP3, or JIP4 were incubated in serum or were serum starved (24 h). Cell lysates were prepared and incubated with the bacterially expressed
TPR domain of KLC fused to GST. Protein complexes were collected on glutathione-agarose, and bound Flag-tagged JIP proteins were detected
by immunoblot analysis. (E and F) The leucine zipper regions of JIP3 and JIP4 interact with the TPR domain of KLC. Bacterially expressed GST
and GST-TPR domain of KLC (GST-KLC) were immobilized on glutathione-agarose and incubated with equal amounts of in vitro-translated and
[35S]methionine-labeled JIP3 or JIP4. Control experiments were performed using [35S]methionine-labeled MLK3 and luciferase. The bound
proteins were detected by SDS-PAGE and autoradiography.
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and JIP4 also has two additional potential phosphorylation
sites (Thr-52 and Thr-61) (Fig. 1A; see Fig. S1 in the supple-
mental material). The presence of these possible phosphory-
lation sites suggests that the functional significance of the in-
teraction of JIP4 with JNK (Fig. 5A) is that JIP4 is a JNK
substrate. To test this hypothesis, we examined JIP4 phosphor-
ylation in an in vitro kinase assay. This analysis demonstrated
that JIP4 is a substrate for JNK (Fig. 8A). JIP4 is also phos-
FIG. 4. Subcellular localization of JIP3 and JIP4. (A) COS cells transfected with Flag-tagged JIP3 or JIP4 were fixed and processed for confocal
microscopy. Control or nocodazole-treated cells were stained (green) with antibodies to Flag-tagged JIP3, Flag-tagged JIP4, or -tubulin. The
nucleus was identified by staining DNA with 4,6-diamidino-2-phenylindole (blue). (B) The possible colocalization of JIP3 or JIP4 (green) with
organelles was examined by staining (red) with mitotracker red (mitochondria) or antibodies to protein disulfide isomerase (endoplasmic
reticulum) or Grasp 65 (Golgi).
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phorylated by p38 MAP kinase but not by ERK2 (Fig. 8A). A
mutational analysis demonstrated that point mutations in any
one of the four potential phosphorylation sites did not prevent
JIP4 phosphorylation by JNK or p38 MAP kinase (data not
shown). In contrast, the simultaneous replacement of all four
phosphorylation sites with Ala residues prevented the phos-
phorylation of JIP4 by JNK and p38 MAP kinase (Fig. 8B).
Together, these data indicate that the sites of JNK phosphor-
ylation are conserved in JIP3 and JIP4. Furthermore, JIP4, but
not JIP3, is also phosphorylated on these sites by p38 MAP
kinase.
JIP4 can potentiate the activation of p38 MAP kinase. Al-
though coimmunoprecipitation analysis indicates that com-
plexes of JIP4 with p38 MAP kinase were not detected (Fig.
5A), the finding that JIP4 is a p38 MAP kinase substrate
demonstrates that JIP4 does interact with p38 MAP kinase
(Fig. 8A). It is most likely that the failure to detect this inter-
action by coimmunoprecipitation analysis is a consequence of
low affinity. To test this hypothesis, we examined the interac-
tions of JNK and p38 MAP kinase with JIP3 and JIP4 by using
[35S]methionine-labeled in vitro-translated protein kinases and
GST-JIP fusion proteins in a more sensitive pull-down assay.
This analysis demonstrated the binding of JNK1, JNK2, and
JNK3 to JIP3 and JIP4 (Fig. 9A). Interestingly, the binding of
JNK to JIP4 was greater than that of JNK to JIP3. No inter-
action between JIP3 and any of the four p38 MAP kinase
isoforms was detected. However, low levels of JIP4 binding to
p38 and p38 MAP kinases were observed (Fig. 9A). No spe-
cific binding of p38 or p38
 MAP kinase to JIP4 was detected,
although some nonspecific binding of p38
 MAP kinase to GST
was observed. Together, these data demonstrate that JIP4,
unlike JIP3, can interact with some p38 MAP kinase isoforms.
The interaction of JIP4 with p38 MAP kinase, along with
the apparent lack of a role for JIP4 as a scaffold for the JNK
signaling pathway, suggests that JIP4 might function to poten-
tiate p38 MAP kinase activation. To test this hypothesis, we
compared the effects of JIP3 and JIP4 on JNK and p38 MAP
kinase activation in cotransfection assays with the MAP3K
FIG. 5. Comparison of protein interactions of JIP3 and JIP4. T7-
tagged JIP3 or JIP4 was expressed in COS cells together with HA-
tagged JNK1, p38 MAP kinase, and ERK2 (A), Flag-tagged MKK7
(B), HA-tagged MLK3 (C), or HA-tagged ASK1 (D). The JIP proteins
were isolated from the cells by immunoprecipitation (IP) with the T7
antibody. JNK, MLK3, and MKK7 binding were examined by immu-
noblot (IB) analysis.
FIG. 6. JIP4 is not a scaffold for the MLK3-MKK7-JNK module.
The effect of JIP3 and JIP4 on MLK3-stimulated JNK1 activity was
examined in a cotransfection assay using COS cells. The levels of
expression of JIP3, JIP4, MLK3, and JNK were examined by immu-
noblot analysis (upper panel). JNK1 activity was measured by using an
immune complex kinase assay with [-32P]ATP and c-Jun as the sub-
strates. The phosphorylated c-Jun was detected following SDS-PAGE
by autoradiography (middle panel) and quantitated by PhosphorIm-
ager (Molecular Dynamics) analysis (lower panel). The data presented
were derived from one experiment. Similar data were obtained in three
independent experiments.
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ASK1. We found that ASK1-stimulated JNK activity was not
potentiated by JIP3 or JIP4 (Fig. 9C). This observation is
consistent with the finding that JIP3 does not form a functional
JNK signaling complex with ASK1 (13) and the conclusion that
JIP4 is not a JNK scaffold (this study). In contrast, JIP4 (but
not JIP3) did potentiate ASK1-stimulated p38 MAP kinase
activation (Fig. 9B). These data suggest that JIP4 may function
as a scaffold for the p38 MAP kinase signaling pathway.
MKK3 and MKK6 are required for p38 MAP kinase acti-
vation by JIP4. Coimmunoprecipitation assays and pull-down
assays using in vitro-translated protein kinases failed to dem-
onstrate an interaction of JIP4 with MAP2Ks that activate JNK
or p38 MAP kinase (MKK3, MKK4, MKK6, and MKK7) (Fig.
5B and data not shown). These data suggest that JIP4 does not
form stable complexes of p38 MAP kinase together with a
MAP2K. Previous studies indicate that p38 MAP kinase can be
activated by a MAP2K-independent mechanism (6, 7). We
therefore considered the possibility that JIP4 may activate p38
MAP kinase by a MAP2K-independent mechanism. To test
this hypothesis, we compared the ability of JIP4 to regulate p38
MAP kinase activity in fibroblasts prepared from wild-type
mouse embryos to that ability in fibroblasts prepared from
MAP2K-deficient mouse embryos (Fig. 10A). We found that
JIP4, but not JIP3, potentiated ASK1-stimulated p38 MAP
kinase activation in wild-type cells (Fig. 10B). Similarly, JIP4
was found to potentiate p38 MAP kinase activation in both
FIG. 7. JIP4 forms homo-oligomers but does not interact with oth-
er JIP proteins. The interactions between JIP proteins were examined.
Flag-tagged JIP3 and JIP4 proteins were coexpressed with T7-tagged
JIP3 or JIP4 (A) and JIP1 or JIP2 (B). The JIP3 and JIP4 proteins
were immunoprecipitated (IP) with the Flag (M2) or T7 antibody. The
coimmunoprecipitation of other JIP proteins was examined by immu-
noblot (IB) analysis. JIP3/4, JIP3 and JIP4; JIP1/2, JIP1 and JIP2.
FIG. 8. JIP4 is a substrate for JNK and p38 MAP kinase but not
ERK2. (A) JIP4 is a substrate for JNK and p38 MAPK but not
ERK2. UV-stimulated JNK1 (upper panel) and p38 MAPK (middle
panel), together with phorbol myristate acetate (PMA)-stimulated
ERK2 (lower panel), were employed in immune complex kinase assays
using [-32P]ATP and GST-JIP3 or GST-JIP4 as the substrates. Con-
trol experiments were performed using known substrates for JNK
(c-Jun), p38 MAPK (ATF2), and ERK2 (Elk-1). The phosphoryla-
tion of the substrates was examined by SDS-PAGE and autoradiogra-
phy. (B) Immune complex kinase assays were performed using wild-
type JIP3 and a mutated JIP3 [JIP3(mu)] protein in which the three
sites of phosphorylation by JNK were replaced with Ala (Thr-266,
Thr-276, and Thr-287). These phosphorylation sites are conserved in
JIP4 (Thr-52, Thr-61, Thr-96, and Thr-112). These Thr phosphoryla-
tion sites were replaced with Ala residues. Wild-type JIP4 and the
mutant JIP4 protein [JIP4(mu)] were examined as substrates for JNK
and p38 MAP kinase. Control experiments were performed using
wild-type and mutant JIP3 proteins for JNK assays (upper panel) and
ATF2 for p38 MAP kinase assays (lower panel).
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Mkk3/ fibroblasts and Mkk6/ fibroblasts (data not shown).
However, JIP4 failed to potentiate p38 MAP kinase activa-
tion in Mkk3/ Mkk6/ compound mutant fibroblasts (Fig.
10C). Together, these data indicate that while the MAP2Ks
MKK3 and MKK6 do not form stable complexes with JIP4,
these MAP2Ks are required for the ability of JIP4 to regulate
p38 MAP kinase activation.
DISCUSSION
We report the identification of JIP4, a new member of the
JIP group of scaffold proteins. The structural organization of
JIP4 is most similar to that of JIP3. Like other members of the
JIP protein group, JIP4 binds to JNK and to the TPR domain
of kinesin light chain. However, unlike other JIP proteins, JIP4
does not activate JNK. In contrast, JIP4 causes MKK3- and
MKK6-dependent activation of p38 MAP kinase.
The murine gene that encodes JIP4 encodes at least three
different proteins: SPAG9, JLP, and JIP4 (Fig. 2). SPAG9, the
sperm-associated antigen 9 protein, was reported to be a trans-
membrane protein with a large extracellular domain and a
short cytoplasmic tail (26). SPAG9 is present on the surface of
sperm and is selectively expressed by spermatids (26). The
function of SPAG9 is unknown. The JLP protein was identified
in a yeast two-hybrid screen using Max, the partner of the
c-Myc transcription factor, as the bait (15). The binding of JLP
to the leucine zipper protein Max is mediated by an NH2-
terminal leucine zipper present in JLP but absent in JIP4 and
SPAG9. JLP binds to Max monomers and can therefore cause
the dissociation of Max homodimers, but JLP is unable to
interact with c-Myc–Max heterodimers and cannot cause the
dissociation of Max from complexes with Myc because the
affinity of the leucine zipper interaction between c-Myc and
FIG. 9. JIP4 can potentiate p38 MAP kinase activation. (A) JIP4
can interact with p38 MAP kinase. JNK and p38 MAP kinases were
in vitro translated in the presence of [35S]methionine and quantitated.
Equal amounts of these proteins were incubated with bacterially ex-
pressed GST, GST-JIP3 (residues 190 through 380), and GST-JIP4
(residues 1 through 150) immobilized on glutathione-agarose beads.
The beads were washed, and bound proteins were detected by SDS-
PAGE and autoradiography. (B) The effect of JIP3 and JIP4 on ASK1-
stimulated p38 activity was examined in cotransfection assays in COS7
cells by using HA epitope-tagged p38 MAPK. The effect of the ex-
pression of ASK1, JIP3, or JIP4 was examined. The levels of expres-
sion of ASK1, JIP3, JIP4, and p38 MAP kinase were examined by
immunoblot analysis. The p38 MAP kinase was immunoprecipitated,
and its activity was measured in an immune complex kinase assay with
[-32P]ATP and ATF2 as substrates. The phosphorylated ATF2 was
detected by SDS-PAGE and autoradiography and was quantitated by
a PhosphorImager analysis. (C) The effects of JIP3 and JIP4 on ASK1-
stimulated JNK activity were examined in a similar assay as shown in
panel B, using HA-tagged JNK1 and c-Jun as the substrates.
FIG. 10. JIP4 requires MKK3 and MKK6 for the potentiation of
p38 MAP kinase activation. (A) Total protein extracts were prepared
from wild-type MEF, Mkk3/ MEF, Mkk6/ MEF, and Mkk3/
Mkk6/ compound mutant MEF. The expression levels of MKK3,
MKK6, and tubulin were examined by immunoblot analysis. (B) The
effects of JIP3 and JIP4 on ASK1-stimulated p38 MAPK activity in
wild-type MEF were examined by cotransfection assays. The activity of
HA-tagged p38 MAP kinase was examined in an immune complex
kinase assay using the substrate ATF2. (C) The effects of JIP3 and JIP4
on ASK1-stimulated p38 MAPK activity in an Mkk3/ Mkk6/
compound mutant MEF were examined by cotransfection assays. The
activity of HA-tagged p38 MAP kinase was examined in an immune
complex kinase assay using the substrate ATF2.
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Max is greater than the affinity of the interaction between JLP
and Max (15). JLP binds multiple protein kinases (JNK, p38
MAP kinase, MKK4, and MEKK3) and has been reported to
act as a scaffold that activates JNK and also recruits potential
transcription factor substrates (15). Although Max is not an
established MAPK substrate, it is possible that other leucine
zipper domain transcription factors that are MAPK substrates
might be recruited by JLP. Interestingly, JIP4 has properties
that are distinct from both JLP and SPAG9. Thus, SPAG9 is a
cell surface transmembrane protein (26) and JLP can interact
with nuclear leucine zipper transcription factors via a unique
NH2-terminal domain (15). In contrast, JIP4 is a cytoplasmic
protein that is largely excluded from the nucleus (Fig. 3 and 4).
The coiled-coil domains of JIP4 can mediate oligomeriza-
tion. Interestingly, although JIP3 and JIP4 can both form
homo-oligomers (most likely dimers), these JIP proteins are
unable to form hetero-oligomers (Fig. 7). However, it is pos-
sible that JIP4 may function as a hetero-oligomer with either
SPAG9 or JLP in vivo. The interaction of JIP4 and either
SPAG9 or JLP may be functionally significant.
Studies of JIP4 indicate that it does not appear to function
as a scaffold for the JNK signaling pathway; for example, JIP4
does not increase JNK activation in transfection assays (Fig. 6
and 9). However, JIP4 was found to potentiate the activation
of p38 MAP kinase (Fig. 9). This analysis suggests that JIP4
may function as a scaffold for the p38 MAP kinase pathway.
This is plausible because JIP4 can bind both p38 MAP kinase
and the MAP3K ASK1. However, an interaction between JIP4
and a MAP2K that can activate p38 was not detected. Gene
disruption studies demonstrated that the MAP2Ks MKK3 and
MKK6 were required for the ability of JIP4 to activate p38
MAP kinase (Fig. 10). In future studies, it will be important to
distinguish between the possibilities that (i) MAP2K binding to
the JIP4 complex is not required for p38 activation, (ii) the
affinity of MAP2K for JIP4 is low but sufficient to form func-
tional complexes with JIP4 in vivo, and (iii) the interaction with
MAP2K is indirect. The last possibility is consistent with pre-
vious studies of the -arrestin-2 scaffold protein that interacts
with ASK1 and JNK3 directly and with MKK4 indirectly by
interactions mediated by both ASK1 and JNK3 (18).
JIP4 may act as a scaffold for the p38 MAP kinase pathway
in vivo. However, the role of the strong interaction of JIP4 with
JNK is unclear. We can speculate on three possibilities. First,
the interaction of JIP4 with JNK may have no physiological
significance. Second, JNK may compete with p38 MAP kinase
for binding to JIP4. Since JNK activation increases binding to
JIP4, it is possible that JNK activation could act to inhibit
JIP4-stimulated p38 MAP kinase activation. Third, JNK bind-
ing to JIP4 is associated with increased phosphorylation of
JIP4 on several sites. It is possible that the phosphorylation of
JIP4 by JNK occurs on sites that regulate JIP4 function. Fur-
ther studies will be required to distinguish between these pos-
sibilities.
A critical goal for future studies will be to determine the
physiological significance of JIP4 by using a loss-of-function
analysis. A knock-down of JIP4 expression using RNA inter-
ference-based methods represents one approach. However, we
have not found this procedure to be effective for JIP4, perhaps
because of the long half-life of the JIP4 protein (unpublished
observations). We have therefore initiated the construction of
Jip4/ mice. We have previously reported the phenotype of
Jip3/ mice (12), and given the similarities between JIP3 and
JIP4, the phenotype of Jip3/ Jip4/ compound mutant an-
imals may be informative. For example, recent studies have
suggested a role for the JIP3 scaffold protein in JNK activation
caused by lipopolysaccharide and mediated by Toll-like recep-
tor 4 (17). Indeed, JIP3 has been reported to bind the cyto-
plasmic domain of Toll-like receptor 4 (17). It is possible that
JIP4 may have a related function in the activation of the p38
MAP kinase signaling pathway.
In conclusion, we report the identification of JIP4, a novel
putative scaffold protein for the p38 MAP kinase pathway. We
propose that JIP4 may regulate p38 MAP kinase activation in
response to specific stimuli in vivo. A similar role for the
scaffold proteins OSM (30) and IB2/JIP2 (3, 24, 25) in the
activation of the p38 MAP kinase pathway has also been pro-
posed. It will be interesting to discover how these scaffold
proteins contribute to the activation of the p38 MAP kinase
pathway by specific stimuli in vivo.
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